An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Dyskinesias; Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms DYSCOVER
- Sponsors AbbVie
- 31 Jan 2018 Planned primary completion date changed from 4 May 2018 to 31 Jan 2020.
- 30 Nov 2017 Planned End Date changed from 18 Jan 2021 to 31 Jan 2020.
- 29 Sep 2017 Planned End Date changed from 19 Sep 2018 to 18 Jan 2021.